Cargando…
Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
BACKGROUND: Alendronate (ALN) is the most common form of bisphosphonates used for the treatment of osteoporosis. Osteoprotegerin (OPG) has also been shown to reduce osteoporotic changes in both humans and experimental animals after systemic administration. The aim of this current study was to test i...
Autores principales: | Wang, Yan, Huang, Peng, Tang, Pei-Fu, Chan, Kai-Ming, Li, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143091/ https://www.ncbi.nlm.nih.gov/pubmed/21752290 http://dx.doi.org/10.1186/1749-799X-6-34 |
Ejemplares similares
-
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010) -
Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications
por: Bjerre, Mette
Publicado: (2013) -
Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease
por: Bolon, B, et al.
Publicado: (2001) -
Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
por: Eid, Riham, et al.
Publicado: (2023) -
Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture
por: Wu, Ying, et al.
Publicado: (2013)